Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Bart Ploeger"'
Publikováno v:
Clinical Pharmacokinetics
Vilaprisan is a highly potent selective progesterone receptor modulator in development for the treatment of symptomatic uterine fibroids and endometriosis. Its pharmacokinetics are characterized by rapid absorption, almost complete bioavailability, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd9a553801a8d3706126ddbfbb5cc38d
https://doi.org/10.1007/s40262-021-01073-3
https://doi.org/10.1007/s40262-021-01073-3
Autor:
Christian Seitz, Kathrin Petersdorf, Bart Ploeger, Matthias Frei, Marcus-Hillert Schultze-Mosgau, Gabriele Sutter
Publikováno v:
British Journal of Clinical Pharmacology. 88:734-741
Aims We report population pharmacokinetic (popPK) and exposure-response (E-R) analyses for efficacy (induced amenorrhoea [IA]) and safety (unbound oestradiol [E2] concentrations) of the selective progesterone receptor modulator vilaprisan. Results we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baf4939dccbd2beda008d60470c1fec3
https://doi.org/10.1111/bcp.15014
https://doi.org/10.1111/bcp.15014
Autor:
Lynley V. Marshall, Irene Jiménez, Andrew D.J. Pearson, Udo Mueller, Adriaan Cleton, Bart Ploeger, Michael Teufel, Patricia Maeda, Sarah Schlief, Bruce Morland, Andrea C. Agostinho, Gilles Vassal, Jasmine Kincaide, Birgit Geoerger, Didier Frappaz
Publikováno v:
European Journal of Cancer. 153:142-152
Background This phase 1 study evaluated safety, pharmacokinetics (PK), maximum tolerated dose (MTD), and antitumour activity of regorafenib in paediatric patients with solid tumours. Patients and methods Patients (aged 6 months to Results Forty-one p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6ce50d56d650acd3c02420f1172c518
https://doi.org/10.1016/j.ejca.2021.05.023
https://doi.org/10.1016/j.ejca.2021.05.023
Autor:
Bart Ploeger, Hauke Rühs, Rolf Burghaus, Sulav Duwal, Walter Schmitt, Dirk Garmann, Michaela Meyer, Thomas Eissing, Christian Diedrich, Jörg Lippert
Publikováno v:
Clinical Pharmacology and Therapeutics
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a well-established biomarker in heart failure (HF) but controversially discussed as a potential surrogate marker in HF trials. We analyzed the NT-proBNP/mortality relationship in real-world dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8ada83935be07d4e368d7615ef04ae0
https://doi.org/10.1002/cpt.2222
https://doi.org/10.1002/cpt.2222
Publikováno v:
British Journal of Clinical Pharmacology
Aim Regorafenib is an oral multikinase inhibitor with clinical efficacy in a range of advanced solid tumours. A population pharmacokinetic (PK) model was developed to evaluate the variability of the PK of regorafenib and its pharmacologically active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2103c08b9cb0ccb6c1b0f624bdf288
https://doi.org/10.1111/bcp.14334
https://doi.org/10.1111/bcp.14334
Autor:
Arash Rezazadeh, Bertrand F. Tombal, Maha H. A. Hussain, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Shivani Kapur, Weijiang Zhang, Bart Ploeger, Rui Li, Iris Kuss, Carsten Zieschang, Sabine Wittemer-Rump, Matthew Raymond Smith
Publikováno v:
Journal of Clinical Oncology. 41:148-148
148 Background: In ARASENS (NCT02799602), DARO in combination with ADT and DOC significantly reduced the risk of death by 32.5% (HR 0.68; 95% CI 0.57–0.80; P2 q21d for 6 cycles). The effect of DARO on DOC PK was assessed by noncompartmental analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc501cea9b8e2f5af6a2742636acd277
https://doi.org/10.1200/jco.2023.41.6_suppl.148
https://doi.org/10.1200/jco.2023.41.6_suppl.148
Autor:
Dirk Garmann, Bart Ploeger, Henk-Jan Drenth, Thomas Eissing, Peter Kolkhof, Nelleke Snelder, Amer Joseph, Jörg Lippert, Roland Heinig
Publikováno v:
Clinical Pharmacokinetics
Background Finerenone (BAY 94-8862) is a potent non-steroidal, selective mineralocorticoid receptor antagonist being developed for the treatment of patients with type 2 diabetes and chronic kidney disease. Methods We present the population pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6c9208a9f324acf3ed71c94f0fdaccf
https://doi.org/10.1007/s40262-019-00820-x
https://doi.org/10.1007/s40262-019-00820-x
Autor:
Bart Ploeger, Tobias Kanacher, Sandra Ligges, Antje Rottmann, Marcus-Hillert Schultze-Mosgau, Manuela Casjens, Joachim Höchel, Niladri Chattopadhyay, Torsten Zimmermann, Sebastian Frechen
Publikováno v:
British Journal of Clinical Pharmacology. 84:2857-2866
Aims The primary aim of the present study was to quantify the effects of rifampicin, a strong cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective progesterone receptor modulator, vilaprisan. In addition, the effects of rif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af2c913ab13e8bcc8653b70270e119e8
https://doi.org/10.1111/bcp.13750
https://doi.org/10.1111/bcp.13750
Autor:
Jordi Bruix, Adriaan Cleton, Alexander Solms, Anne Keunecke, Isabel Reinecke, Bart Ploeger, Gerold Meinhardt, Henk-Jan Drenth, Sabine Fiala-Buskies
Publikováno v:
European Journal of Pharmaceutical Sciences. 109:S149-S153
To explore the relationship between regorafenib exposure and efficacy in patients with hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment (RESORCE).Exposure-response (ER) analyses for regorafenib were performed usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6de012834797411d2dc15a65043b82
https://doi.org/10.1016/j.ejps.2017.05.050
https://doi.org/10.1016/j.ejps.2017.05.050
Autor:
Olaf Prien, Iris Kuss, Kristina Graudenz, Karim Fizazi, Bart Ploeger, Gustavo Borghesi, Teuvo L.J. Tammela, Neal D. Shore, Robert Fricke, Jonathan Moss, Hille Gieschen, Oana Petrenciuc, Frank Verholen, Christian Zurth, Mikko Koskinen, Matthew R. Smith
Publikováno v:
Targeted Oncology
Background Darolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metastasis-free survival versus placebo in the phase III ARAMIS study in men with nonmetastatic castration-resistant prostate cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac2f03eb3e89dd93f921111daaa43d3
https://pubmed.ncbi.nlm.nih.gov/31571095
https://pubmed.ncbi.nlm.nih.gov/31571095